Axsome Therapeutics Financial Statements (AXSM)
|
|
|
|
Report date
|
|
|
04.08.2025 |
03.11.2025 |
23.02.2026 |
04.05.2026 |
10.08.2026 |
|
04.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
150.0 |
171.0 |
196.0 |
191.2 |
218.4 |
|
708.2 |
|
Operating Income, bln rub |
|
|
-36.7 |
-46.1 |
-29.4 |
-63.4 |
-49.6 |
|
-175.6 |
|
EBITDA, bln rub |
? |
|
-42.6 |
-44.4 |
-24.7 |
-61.1 |
-49.6 |
|
-172.7 |
|
Net profit, bln rub |
? |
|
-48.0 |
-47.2 |
-28.6 |
-64.5 |
-51.3 |
|
-188.3 |
|
|
OCF, bln rub |
? |
|
-32.4 |
1.05 |
-18.7 |
-20.7 |
-33.0 |
|
-70.7 |
|
CAPEX, bln rub |
? |
|
0.013 |
0.058 |
0.071 |
0.121 |
0.121 |
|
0.263 |
|
FCF, bln rub |
? |
|
-32.4 |
0.988 |
-18.7 |
-20.8 |
-32.8 |
|
-71.0 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
|
OPEX, bln rub |
|
|
173.3 |
205.2 |
213.1 |
239.8 |
254.5 |
|
831.4 |
|
Cost of production, bln rub |
|
|
13.4 |
11.9 |
12.3 |
14.7 |
13.6 |
|
52.4 |
|
R&D, bln rub |
|
|
49.5 |
40.2 |
48.8 |
52.7 |
46.2 |
|
191.2 |
|
Interest expenses, bln rub |
|
|
1.83 |
1.12 |
1.17 |
1.19 |
1.54 |
|
5.31 |
|
|
Assets, bln rub |
|
|
639.8 |
669.3 |
689.8 |
713.6 |
761.4 |
|
713.6 |
|
Net Assets, bln rub |
? |
|
73.1 |
73.7 |
88.3 |
54.6 |
83.3 |
|
54.6 |
|
Debt, bln rub |
|
|
217.3 |
218.6 |
241.3 |
219.9 |
219.2 |
|
216.7 |
|
Cash, bln rub |
|
|
303.0 |
325.3 |
322.9 |
305.1 |
319.9 |
|
305.1 |
|
Net debt, bln rub |
|
|
-85.7 |
-106.7 |
-81.6 |
-85.2 |
-100.6 |
|
-88.4 |
|
|
Ordinary share price, rub |
|
|
104.4 |
121.5 |
182.6 |
169.0 |
244.8 |
|
169.0 |
|
Number of ordinary shares, mln |
|
|
49.4 |
50.0 |
50.6 |
51.2 |
51.5 |
|
51.2 |
|
|
Market cap, bln rub |
|
|
5 161 |
6 075 |
9 247 |
8 654 |
12 606 |
|
8 654 |
|
EV, bln rub |
? |
|
5 076 |
5 968 |
9 166 |
8 568 |
12 505 |
|
8 565 |
|
Book value, bln rub |
|
|
17 |
20 |
36 |
4 |
34 |
|
4 |
|
|
EPS, rub |
? |
|
-0.97 |
-0.94 |
-0.56 |
-1.26 |
-1.00 |
|
-3.68 |
|
FCF/share, rub |
|
|
-0.66 |
0.02 |
-0.37 |
-0.41 |
-0.64 |
|
-1.39 |
|
BV/share, rub |
|
|
0.35 |
0.39 |
0.71 |
0.07 |
0.66 |
|
0.07 |
|
|
EBITDA margin, % |
? |
|
-28.4% |
-26.0% |
-12.6% |
-31.9% |
-22.7% |
|
-24.4% |
|
Net margin, % |
? |
|
-32.0% |
-27.6% |
-14.6% |
-33.8% |
-23.5% |
|
-26.6% |
|
FCF yield, % |
? |
|
-2.34% |
-1.67% |
-1.02% |
-0.82% |
-0.57% |
|
-0.82% |
|
ROE, % |
? |
|
-337.9% |
-311.3% |
-207.5% |
-345.0% |
-230.1% |
|
-345.0% |
|
ROA, % |
? |
|
-38.6% |
-34.3% |
-26.6% |
-26.4% |
-25.2% |
|
-26.4% |
|
|
P/E |
? |
|
-20.9 |
-26.5 |
-50.5 |
-46.0 |
-65.8 |
|
-46.0 |
|
P/FCF |
|
|
-42.7 |
-59.9 |
-98.5 |
-121.9 |
-176.6 |
|
-121.9 |
|
P/S |
? |
|
10.4 |
10.8 |
14.5 |
12.2 |
16.2 |
|
12.2 |
|
P/BV |
? |
|
298.3 |
310.6 |
258.8 |
2 405 |
371.8 |
|
2 405 |
|
EV/EBITDA |
? |
|
-22.2 |
-28.1 |
-55.1 |
-49.6 |
-69.6 |
|
-49.6 |
|
Debt/EBITDA |
|
|
0.38 |
0.50 |
0.49 |
0.49 |
0.56 |
|
0.51 |
|
|
R&D/CAPEX, % |
|
|
381 085% |
69 245% |
68 720% |
43 535% |
38 204% |
|
72 689% |
|
|
CAPEX/Revenue, % |
|
|
0.01% |
0.03% |
0.04% |
0.06% |
0.06% |
|
0.04% |
|
| Axsome Therapeutics shareholders |
